Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)
This study will look to see how well patients with relapsed or recurrent intracranial germ cell tumors respond to the new combination of chemotherapy (in induction)of Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) followed by consolidation chemotherapy and autologous stem cell rescue.
CNS Germ Cell Tumor
DRUG: Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).
Response rate, To estimate response rate after at least two and up to four courses of induction chemotherapy with GemPOx regimen in patients with recurrent intracranial MMGCT, 4 months
Toxicity levels, To assess the toxicity of GemPOx regimen in all patients with ICGCT (pure germinoma and MMGCT), 4 months
This study will look to see how well patients with relapsed or recurrent intracranial germ cell tumors respond to the new combination of chemotherapy (in induction)of Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) followed by consolidation chemotherapy and autologous stem cell rescue.